Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. - Wikidata - wikimedia - TriplyDB

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.

http://www.wikidata.org/entity/Q33950898

about

Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis The chronic gastrointestinal consequences associated with campylobacter.Health utility of patients with Crohn's disease and ulcerative colitis: a systematic review and meta-analysis.A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease.Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review.Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

P2860

Q26777634-364B8302-2806-4165-8CBF-E6B8CBAD7E42 Q33598247-7FA2CFE6-A109-4832-A8F1-B59D1FB0D6C3 Q38032174-6A199191-9D89-4502-9080-DD38E4A827CF Q38836219-B09ED6B0-57D2-4518-94F3-7A14AA37906B Q42369594-4EE795A0-2E1E-4368-8166-1569E19ED728 Q55690473-337D2556-B66C-4C39-A055-77F1B2163D27 Q57193103-AAF47045-68AA-480C-9AF8-AF0CC5C9D932

P2860

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.

http://www.wikidata.org/entity/Q33950898

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cost effectiveness of ulcerati ...... al formulations of mesalazine.

@ast

Cost effectiveness of ulcerati ...... al formulations of mesalazine.

@en

type

label

Cost effectiveness of ulcerati ...... al formulations of mesalazine.

@ast

Cost effectiveness of ulcerati ...... al formulations of mesalazine.

@en

prefLabel

Cost effectiveness of ulcerati ...... al formulations of mesalazine.

@ast

Cost effectiveness of ulcerati ...... al formulations of mesalazine.

@en

P1433

Q33950898-6E5A6A20-5791-47BA-B3E3-E714C29D1034

P1476

Q33950898-CE83D6AE-1090-4CE0-B0CC-594DE9EFCF7F

P2093

Q33950898-0484FFB4-B71B-4B0D-B4B1-F5AAB2A65ED2

Q33950898-34CBB84C-78A6-4707-AE32-267C4ABAD0F5

Q33950898-83F1AECE-CC78-49B1-885C-153515AE464B

Q33950898-897AC1F7-C927-4ADC-88FB-C8EDAE9E4D59

P2860

Q33950898-051AF1AB-4A0A-4FA9-995A-CEE500817379

Q33950898-09F5E8C8-45A6-4E22-9D2F-A891C5D1A500

Q33950898-106115F6-F10C-4AEC-826C-353BF59493B4

Q33950898-166F6929-2B1A-4F23-B099-7C9F721EE825

Q33950898-2E58242C-C0AB-45D0-8616-3F1A0DAC5A76

Q33950898-2EBB96AE-8C19-4350-BC76-10F6011E1F7F

Q33950898-39360B04-5FF2-4A6A-B87E-F62720B90636

Q33950898-6B8585F5-5EE8-4669-B4C1-106783A43927

Q33950898-6C3D0847-2766-43A1-9CDD-B66C98EE2FFC

Q33950898-70878D74-C8C4-4B89-BC35-4D4006917E55

P2888

Q33950898-C017BBF8-86CC-468C-91E7-EFDB4FF0AA8F

P304

Q33950898-CA220AB0-4CB8-43A7-822A-CF581D47FBA0

P31

Q33950898-F1872A0C-987B-43D9-8529-64DE388FFD83

P356

Q33950898-162CCC0F-AAF6-44BC-AACE-75C564C829F9

P478

Q33950898-2C247F47-1673-438B-905C-97AE380822AC

P577

Q33950898-9882EB78-18F0-440B-A24E-52943072D3C2

P5875

Q33950898-4B212484-F29B-4DEB-8A77-3858055B095E

P6179

Q33950898-AD2E158A-28CE-4CEE-95C8-8997969B6B20

P698

Q33950898-25A5D14B-81D2-416F-983C-0EFD3211D8FE

P921

Q33950898-D5B5AE79-349D-41F4-B1CA-D9C1D6A84656

P932

Q33950898-F6A4EA30-0C86-42DA-992E-0A6510D81CF7

P356

1472-6963-11-157

P1433

BMC Health Services Research

P1476

Cost effectiveness of ulcerati ...... al formulations of mesalazine.

@en

P2093

Anne Prenzler

http://www.w3.org/2001/XMLSchema#string

J-Matthias von der Schulenburg

http://www.w3.org/2001/XMLSchema#string

Linnette Yen

http://www.w3.org/2001/XMLSchema#string

Thomas Mittendorf

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammatory bowel disease: clinical aspects and established and evolving therapies

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.

Systematic review: adherence issues in the treatment of ulcerative colitis.

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.

A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.

An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis.

Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.

P2888

1472-6963-11-157

P304

157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1472-6963-11-157

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51467352

http://www.w3.org/2001/XMLSchema#string

P6179

1022984464

http://www.w3.org/2001/XMLSchema#string

P698

21729262

http://www.w3.org/2001/XMLSchema#string

P921

P932

3146407

http://www.w3.org/2001/XMLSchema#string